Prostate cancer is a hormone-driven disease and its tumor cell growth highly relies on
increased androgen receptor (AR) signaling. Therefore, targeted therapy directed against …

Histone methylation is a key posttranslational modification of chromatin, and its
dysregulation affects a wide array of nuclear activities including the maintenance of genome …

Prostate cancer is the most common non-cutaneous cancer and the second leading cause
of cancer-associated deaths among men in the United States. Androgen deprivation therapy …

Decades of research into the molecular mechanisms of cancer and the development of
novel therapeutics have yielded a number of remarkable successes. However, our ability to …

Genomic loss of RB1 is a common alteration in castration-resistant prostate cancer (CRPC)
and is associated with poor patient outcomes. RB1 loss is also a critical event that promotes …

Context In addition to genetic alterations, epigenetic alterations play a crucial role during
prostate cancer progression. A better understanding of the epigenetic factors that promote …

The androgen receptor (AR) signaling pathway is critical for growth and differentiation of
prostate cancer cells. For that reason, androgen deprivation therapy with medical or surgical …

The use of androgen deprivation therapy and second line anti-androgens in prostate cancer
has led to the emergence of tumors employing multiple androgen receptor (AR)-dependent …

Neuroendocrine (NE) differentiation in metastatic castration-resistant prostate cancer
(mCRPC) is an increasingly common clinical feature arising from cellular plasticity. We …

Background Antisense oligonucleotide (ASO) medicine for clinical applications has been
becoming a reality. We previously developed a gapmer ASO targeting Ser/Arg repetitive …